John Mendelsohn
Annual Plan:2019-2020
Developing an RNA-based Strategy for Actionable Target Assessment to Personalize Cancer Therapies
At the end of the project proposed by 2018 laureate Dr. Mendelsohn's team, it is expected that a multiplex assay will be developed to rapidly screen for ADC targets, enabling scientists to match patient with ADCs or bio-specific drugs that suit them and to reach our goal of personalizing cancer therapies.